Skip to content

Author

S. M. Taghdisi

We have 2 of 357 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

CRISPR/Cas12a-based tag-free fluorescent biosensor using G-quadruplex specific thioflavin T for detection of oncogenic microRNAs.

MicroRNAs (miRs) are central regulators of tumor initiation and progression, and their aberrant expression patterns have been identified as clinically valuable biomarkers for the early diagnosis of malignancies and prognostic evaluation. Here, we report tag-free fluorescence biosensing platform for the detection of circulating miRs in serum, targeting microRNA-21 (miR-21) and microRNA-10b (miR-10b) as clinically relevant oncogenic markers. The assay integrates CRISPR/Cas12a-mediated signal regulation with complementary strand (CS)-mediated target recognition. In this strategy, target miRs hybridize with the CS, thereby preventing CS-mediated activation of the Cas12a-crRNA complex. As a result, Cas12a collateral cleavage is suppressed, the G-quadruplex reporter remains intact, and Thioflavin T fluorescence is enhanced. The platform demonstrated excellent sequence discrimination capability, effectively distinguishing closely related and mismatched targets. Sensitive quantification was achieved with limits of detection of 1.4 nM for miR-21 and 852 pM for miR-10b. Importantly, robust analytical performance was maintained in complex biological matrices, confirming its applicability to serum samples. Collectively, this CRISPR/Cas12a-enabled fluorescent biosensor provides a simple approach for circulating miR detection.

Sepideh Hassibian, Masoomeh Esmaelpourfarkhani, M. Alibolandi et al. · 0 citations
Review Jul 2026

Therapeutic platforms for cancer management centered on blocking the PD-L1/PD-1 interaction through the use of aptamers: A review.

A comprehensive analysis of aptamer-driven strategies aimed at inhibiting the PD-1/PD-L1 immune checkpoint pathway is provided, summarizes recent advances in the design of PD-1/PD-L1-targeted aptamer systems and evaluates their potential to enhance therapeutic efficacy while addressing challenges related to immune resistance.

Abolfazl Marvizadeh, Elham Sameiyan, Amir Teymour Najjarkar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.